

**smith & hopewell, p.a.**

Intellectual Property Law Patents Trademarks Copyrights

September 16, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Applicants: Thomas Freeman et al.**  
**Serial No.: 10/604,591**  
**Filing Date: 08/01/2003**  
**For: Method of Treating Herpes Virus Infections**  
**Our Reference No.: 1372.50**

**Examiner: Unassigned**  
**Art Unit: Unassigned**

Dear Sir:

Enclosed please find the following:

1. Information Disclosure Statement By Applicants- 2 pages;
2. Copies of three (3) U.S. Patent Documents;
3. Copies of seventeen (17) Non-Patent Literature Documents; and
4. Self-addressed, postage-prepaid postcard to serve as a receipt for items 1-3.

Very respectfully,

**SMITH & HOPEN**

By: Anton J. Hopewell  
*anton.hopewell@baypatents.com*

AJH/sb  
enclosure

**CERTIFICATE OF MAILING**  
(37 C.F.R. 1.8)

I HEREBY CERTIFY that this correspondence is being mailed with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 16, 2003.

Date: September 16, 2003


Shelley Butz

*Attorney-Client Privileged Communication*

15950 Bay Vista Drive, Suite 220 Clearwater, Florida 33760, USA  
Phone: (727) 507-8558 Fax: (727) 507-8668  
Internet: [www.baypatents.com](http://www.baypatents.com)

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
		Application Number	10/604,591
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	08/01/2003
		First Named Inventor	Thomas Freeman et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	1372.50
Sheet	3	of	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	LANGEVIN ET AL.; Rabies Virus Glycoprotein (RVG) is a Trimeric Ligand for the N-Terminal Cysteine-rich Domain of the Mammalian p75 Neurotrophin Receptor; Journal of Biological;	
	5	THOMAS FREEMAN; The Prospects for Vaccination Against Herpes Viruses; Power Point Presentation; 2001	
	6	Herpesvirus Replication; <a href="http://darwin.bio.uci.edu/~faculty/wager/movietext.html">http://darwin.bio.uci.edu/~faculty/wager/movietext.html</a> ; 9/5/2001	
	7	EISENBERG, Ph.D.; University of Pennsylvania School of Veterinary Medicine; 9/5/2001	
	8	FERSON; Varicella Vaccine in Post-Exposure Prophylaxis; <a href="http://health.gov.au/pubhlth/cdi2501/cdi2501e.htm">http://health.gov.au/pubhlth/cdi2501/cdi2501e.htm</a> ; 9/5/2001	
	9	KUTER ET AL.; Efficacy of OKA/Merck Varicella Vaccine After Concomitant Administration with M-M-R II; 9/5/2001	
	10	Varicella Virus Vaccine Live (Oka/Merck); <a href="http://www.geocities.com/mom2q/CPVaccineInsert.htm">www.geocities.com/mom2q/CPVaccineInsert.htm</a> ; 9/5/2001	
	11	Facts About Shingles (Varicella-Zoster Virus); <a href="http://www.niaid.nih.gov/factsheetsFS.htm">www.niaid.nih.gov/factsheetsFS.htm</a> ; 9/5/2001	
	12	EHRMAN; A Potential Shingles Vaccine; <a href="http://www.nih.gov/news/WordonHealth/oct2000/story03.htm">www.nih.gov/news/WordonHealth/oct2000/story03.htm</a> ; 10/2000	
	13	History of Rabies; <a href="http://justice.loyola.edu/~klc/BL472/Rabies/rabies~1.htm">http://justice.loyola.edu/~klc/BL472/Rabies/rabies~1.htm</a>	
	14	MASCOLA; Herpes Simplex Virus Vaccines - Why Don't Antibodies Protect?; <a href="http://jama.ama-assn.org/issues/v282n4/full/jed90053.html">http://jama.ama-assn.org/issues/v282n4/full/jed90053.html</a> ; Vol 282, No. 4; 7/28/1999	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type and sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/604,591
		Filing Date	08/01/2003
		First Named Inventor	Thomas Freeman et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	1372.50
Sheet	3	of	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	15	COREY ET AL.; Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection; American Medical Association; 7/28/1999; Vol. 282, No. 4, pg.331-340	
	16	The Big Picture Book of Viruses: Herpesviridae; www.virology.net/Big_Virology/BVDNAherpes.html; 9/5/2001	
	17	Virus Antigens; www.virotest.com/products3_e.htm; 9/5/2001	
	18	IMOGAM Rabies Pasteurized [Rabies Immune Globulin, Pasteurized (Human)];	
	19	SHERMAN, R.Ph.D.; Rabies: A History and Update on Prophylaxis Regimens in the U.S.; www.uspharmacist.com/NewLook/DisplayArticle.cfm?item_num=563; 11/26/2001	
	20	IMOVAX Rabies [Rabies Vaccine Inactivated (DCO)]	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+